Answers are grounded in this paper and cite their sources.
No difference was found in the composite outcome of 60-day bacteremia recurrence, readmission, or inpatient infection-related mortality for patients with MRSA bacteremia retained on combination therapy versus those de-escalated to monotherapy.
No takes yet. Share an insight, caveat, or question.
Nichols et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: